VACCITECH (SP.ADR)/1 Total Assets
VACCITECH (SP.ADR)/1 total assets. Based on the latest financial reports, VACCITECH (SP.ADR)/1 (2AB) holds total assets worth €92.14 Million EUR (≈ $107.72 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VACCITECH (SP.ADR)/1 market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of VACCITECH (SP.ADR)/1 (2021–2025)
Total assets of VACCITECH (SP.ADR)/1 from 2021 to 2025. This chart illustrates how VACCITECH (SP.ADR)/1's total assets have evolved over time, based on quarterly financial data. See VACCITECH (SP.ADR)/1 stock price for real-time trading data and today's change.
VACCITECH (SP.ADR)/1 - Asset Composition Analysis
VACCITECH (SP.ADR)/1 Total Assets Breakdown (December 2025)
VACCITECH (SP.ADR)/1 total assets breakdown as of December 2025. VACCITECH (SP.ADR)/1's total assets of €92.14 Million consist of 79.2% current assets and 20.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 71.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how VACCITECH (SP.ADR)/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore VACCITECH (SP.ADR)/1 (2AB) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VACCITECH (SP.ADR)/1's current assets represent 79.2% of total assets in 2025, a decrease from 80.8% in 2021.
- Cash Position: Cash and equivalents constituted 71.8% of total assets in 2025, down from 76.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 15.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
VACCITECH (SP.ADR)/1 Competitors by Total Assets
Key competitors of VACCITECH (SP.ADR)/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
VACCITECH (SP.ADR)/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.05 | 9.18 | 8.93 |
| Quick Ratio | 6.05 | 9.18 | 8.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €60.66 Million | €97.91 Million | €119.58 Million |
VACCITECH (SP.ADR)/1 - Advanced Valuation Insights
This section examines the relationship between VACCITECH (SP.ADR)/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.40 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -38.8% |
| Total Assets | €98.17 Million |
| Market Capitalization | $20.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values VACCITECH (SP.ADR)/1's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: VACCITECH (SP.ADR)/1's assets decreased by 38.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VACCITECH (SP.ADR)/1 (2021–2025)
The table below shows the annual total assets of VACCITECH (SP.ADR)/1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €98.17 Million ≈ $114.77 Million |
-38.77% |
| 2024-12-31 | €160.33 Million ≈ $187.44 Million |
-25.26% |
| 2023-12-31 | €214.51 Million ≈ $250.78 Million |
-20.61% |
| 2022-12-31 | €270.20 Million ≈ $315.90 Million |
-3.74% |
| 2021-12-31 | €280.71 Million ≈ $328.19 Million |
-- |
About VACCITECH (SP.ADR)/1
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more